knowledge -WSS

knowledge

author：knowledge 2025-09-30 14:58:47 - browse：662

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

The release of Novo Nordisk’s latest earnings report on Thursday provided a chance for executives to tout their major win this week — outcomes from a large trial showing the company’s obesity drug Wegovy cut the risk of heart complications by 20%.

But once again, much of the attention was focused on the company’s struggles to meet what Novo CEO Lars Fruergaard Jørgensen referred to as the “overwhelming demand for Wegovy.”

Jørgensen reiterated that the company was racing to expand supply and had brought on more contract manufacturing support, but Novo said Thursday that the company would continue to restrict the availability of lower-strength starter doses in the United States to ensure that patients on the drug would not have their medication interrupted.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Patients' immediate access to test results puts radiologists in a bind

leisure time

WSS

Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

The thinking behind the controversial eating disorder chatbot Tessa

Inside the rise of 'mukbang' eating videos

Chemotherapy shortages won’t get better under Biden’s latest plan

In diabetes hearing, Sanders takes on a new foe: food makers

AI models in health care face new federal disclosure requirements

leisure time

knowledge

hotspot

Supreme Court strikes down use of affirmative action

Pregnancy discrimination could be enabled by AI

United colonoscopy coverage change 'may cost lives,' doctors say

Xenotransplantation trials will require adjusting expectations, experts say

As demand for Covid shots wanes, Moderna seeks its next success

Inside the rise of 'mukbang' eating videos

FDA approval of Sarepta Duchenne genetic therapy gives me hope

FDA approves first new drug developed for postpartum depression

Hepatitis C has a cure — but many Americans still lack access to it

In diabetes hearing, Sanders takes on a new foe: food makers

hotspot

Eli Lilly’s Mounjaro succeeds in second weight

Pregnancy discrimination could be enabled by AI

Timeline: Key moments in fight for gay rights

Bispecific antibodies are next new thing in cancer immunotherapy

Pharma patents targeted by Biden in move to slash drug prices

Pregnancy discrimination could be enabled by AI

leisure time

focus

hotspot

leisure time